Gentian Diagnostics
Manufacturing · Norway · 51-200 Employees
View Company Info for Free
Overview
Headquarters
PO Box 733, Moss, Ostfold, 1509, NorwayPhone Number
+4799339905Website
www.gentian.comRevenue
$19.2 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Gentian Diagnostics
Gentian Diagnostics ASA is a fast-growing developer and manufacturer of innovative in-vitro diagnostic (IVD) products designed for the detection and quantification of specific biomarkers related to kidney disease, cardiac disease, inflammation, infection, and veterinary medicine. Their product portfolio includes assays such as Calprotectin, Cystatin C, and Canine CRP, which are compatible with various clinical chemistry analysers. The company serves a global market through OEM partnerships, key distributors, and healthcare providers, focusing on delivering efficient diagnostics that enhance treatment decisions. Gentian is committed to innovation and seeks to address high-value markets with accurate diagnostic tests that reduce time and costs for laboratories and patients.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gentian Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Gentian Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Gentian Diagnostics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Gentian Diagnostics launches new products
Check out if Gentian Diagnostics is spiking on competitors!
Earning: See what the market has to say on Gentian Diagnostics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Gentian Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Gentian Diagnostics has new funding data
Click to see if Gentian Diagnostics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Gentian Diagnostics
Find more new buyers
Company Profile Activity
Activity Insights
Gentian Diagnostics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gentian Diagnostics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gentian Diagnostics.
Gentian Diagnostics Tech Stack
A closer look at the technologies used by Gentian Diagnostics
Most Recent Scoops
Earnings
Gentian has reported revenues of NOK 8.2 million from its other products category, including cCRP, fPELA, GCAL, and RBP, for Q2 2026, representing 16% growth compared to NOK 7.1 million in the same quarter last year, with fPELA delivering growth clearly above that of fCAL during both Q2 and H1 2026.
Earnings, Finance
Project
Gentian is increasing investment in its high-sensitivity PETIA technology, which has demonstrated up to 100-fold improvement in sensitivity compared to traditional assays, with the company estimating this advancement could bring approximately 100 additional biomarkers within reach for turbidimetric assay development across both point-of-care and core laboratory instrument platforms.
Spending/Investment, Research & Development
Earnings
Gentian has reported R&D expenses of NOK 9 million for Q2 2026, compared to NOK 6.7 million in Q2 2025, with the increase attributable to a change in accounting policy whereby all R&D expenses are now recognized through the profit and loss statement rather than capitalized, resulting in a NOK 4.2 million capitalization effect in H1 2026 that reduced total OpEx by 3% on an adjusted basis versus Q2 2025.
Earnings, Research & Development, Accounting, Financial Reporting, Finance
Earnings
Gentian has reported a cash position of NOK 79.3 million and a free cash flow of negative NOK 3.3 million for Q2 2026, with the cash outflow driven by working capital movements, following the payment of NOK 9.3 million in dividends, representing a 50% increase over the prior year's dividend payment.
Earnings, Accounting, Financial Reporting, Business Finance, Finance, Financial Operations
Earnings
Earnings, Contracts, Finance
Gentian Diagnostics News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gentian Diagnostics
Sign Up For FreeTo access detailed company insights
Gentian Diagnostics ASA is a fast-growing developer and manufacturer of innovative in-vitro diagnostic (IVD) products designed for the detection and quantification of specific biomarkers related to kidney disease, cardiac disease, inflammation, infection, and veterinary medicine. Their product portfolio includes assays such as Calprotectin, Cystati... Read More
